Search for a trial

The value of additional MR-Ultrasound fusion guided biopsies to standard Navigo*-based biopsies in the diagnosis of prostate cancer

Primary objectiveTo determine whether adding the MRI/US fusion technique using mpMRI images for directed biopsy of a ROI leads to a higher detection rate of PCa per patient compared to a systematic 12-core biopsy protocol including directed biopsy…

REQUITE: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality-of-life in cancer survivors

Primary ObjectiveTo establish a prospective cohort of patients undergoing radiotherapy for breast, prostate or lung cancers following local regimens and collecting standardised radiotherapy toxicity data, non genetic risk factor data and samples for…

Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)

To validate two novel genomic biomarkers that provide information with respect to the presence of PCa, disease aggressiveness, and progression towards recurrent and metastatic disease.

A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide Alone.

The primary objective of this research is to compare the efficacy of continuing treatment with enzalutamide after adding docetaxel and prednisolone versus placebo plus docetaxel and prednisolone, as measured by progression-free survival (PFS) in…

An Open-label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer.

The purpose of this study is to evaluate the effect of a single dose of JNJ-56021927 on the heart*s electrical activity and to see how the body processes the study drug in subjects with Castration-Resistant Prostate Cancer.Further the safety of JNJ-…